Search for: "SANOFI-PHARMACEUTICALS, INC." Results 21 - 40 of 216
Sorted by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
26 Jul 2016, 8:45 pm by Patent Docs
Zydus Pharmaceuticals (USA) Inc. 1:16-cv-00540; filed June 29, 2016 in the District Court of Delaware Plaintiffs: Genzyme Corp.; Sanofi-Aventis U.S. [read post]
27 Nov 2022, 8:10 pm by Patent Docs
Paul Berghoff of McDonnell Boehnen Hulbert & Berghoff LLP will moderate a panel consisting of Larry Coury of Regeneron Pharmaceuticals, Inc.; Stephanie Donahue of Sanofi; Henry Hadad of Bristol-Meyers Squibb Co.; and Stuart Watt of Amgen, Inc. that will discuss the issues and arguments concerning the current state of enablement and written description law and where the law may be headed. [read post]
5 Feb 2018, 9:59 pm by Patent Docs
Mylan Pharmaceuticals, Inc. v. [read post]
15 Mar 2016, 9:00 am by Suzette Pringle
On March 4, 2016, the Second Circuit affirmed the dismissal of two related securities actions against Sanofi Pharmaceuticals, its predecessor Genzyme Corporation, and three company executives (collectively, “Sanofi”). [read post]
23 Mar 2009, 2:26 pm
The case addressed a dispute arising between the brand-name pharmaceutical manufacturer, Sanofi, and the Canadian generic manufacturer, Apotex. [read post]
5 Aug 2021, 7:38 pm by Patent Docs
The product is Semglee (insulin glargine-yfgn), produced by Mylan Pharmaceuticals, Inc., and under this approval, it is interchangeable with Lantus (insulin glargine) made by Sanofi. [read post]
28 Dec 2011, 4:46 pm
San Diego - Genentech filed suit against Regeneron Pharmaceuticals and Sanofi Inc. on December 23, 2011 in the United States District Court, Southern District of New York. [read post]
14 Mar 2014, 1:02 pm
The individual filed suit in Cook County Circuit Court against Bristol-Myers Squibb Co., Sanofi-Aventis US LLC, Sanofi-Aventis US Inc., and Sanofi-Synthelabo Inc. in a claim of strict product liability, manufacturing defect, negligence, and failure to warn. [read post]
2 Apr 2011, 11:58 pm
Sanofi-Aventis sued Sun Pharmaceutical for its generic mimic of a cancer treatment drug, oxaliplatin. [read post]
15 Jun 2014, 8:46 pm by Patent Docs
.; Glenmark Generics Inc., USA • Defendant: Ferring, B.V. [read post]
5 Sep 2017, 7:45 am by Ben Vernia
According to DOJ’s press release: Pharmaceutical companies Mylan Inc. and Mylan Specialty L.P. have agreed to pay $465 million to resolve claims that they violated the False Claims Act by knowingly misclassifying EpiPen as a generic drug to avoid paying rebates owed primarily to Medicaid, the Justice Department announced today. [read post]
2 Jun 2009, 2:56 pm
The Department of Justice announced last week that it has entered into a multi-million dollar civil settlement agreement with Aventis Pharmaceutical, Inc., a subsidiary of Sanofi Aventis U.S. [read post]
15 Oct 2020, 9:40 pm by Kirk Hartung
” In the first IPR, Sanofi-Aventis, Genzyme Corp., and Regeneron Pharmaceuticals (collectively “Sanofi”) challenged the ‘487 patent, and the PTAB found all of the challenged claims to be invalid. [read post]
24 Apr 2014, 9:59 pm by Patent Docs
By Michael Greenfield -- On April 21, 2014, a Federal Circuit panel reiterated its interpretation and application to the chemical arts of the KSR obviousness standard. [read post]
8 Jan 2009, 12:38 pm
  On March 31, 2005, one year into the FDA review of the generic manufacturers' ANDA submissions, Defendants Aventis Pharmaceuticals, Inc., Sanofi-Aventis, and Sanofi-Aventi U.S., LLC (collectively "Aventis") filed a Citizen Petition pursuant to Section 505(j) of the Federal Food, Drug, and Cosmetic Act. [read post]
16 Jun 2010, 2:04 am by gmlevine
Pharmaceuticals (Sanofi-Aventis), banks and finance (Citigroup, Inc., MasterCard International Incorporated) , fashion (Christian Dior Couture), retail (Harrods Limited, Burberry Limited), hotels and travel (Sheraton International Inc.), automobiles (Bayerische Motoren Werke AG (BMW AG)) and toy manufacturers (LEGO Juris A/S) are frequent targets. [read post]